Pharma Industry News
A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.
I just bought this pharma stock for its next generation of blockbuster drugs - and its dividend
We just initiated a new position in AbbVie Inc. at around $280 a share for our Enhanced Dividend Income Portfolio. While the dividend is certainly part of the appeal, I'm really into the company's next chapter of growth. The North Chicago-based…
Chinese pharma players take center stage at ESMO 2026, highlighting growing global influence
Photo: Hengrui's exhibition booth at ESMO Congress 2026 Chinese-developed cancer drugs achieved a record level of representation at one of the world's leading oncology conferences, from more prominent time slots to higher number of drug…
Piramal Pharma Limited Announces Results for Q2 and H1 FY27
MUMBAI, India, Oct. 27, 2026 /CNW/ -- Piramal Pharma Limited (NSE: PPLPHARMA | BSE: 543635), a leading global pharmaceutical, health and wellness company, today announced its standalone and consolidated results for the Second Quarter (Q2) and Half…
Piramal Pharma looks to a 'significantly stronger' second half of the year: Nandini Piramal
The company posted a net profit of ₹5 crore for the second quarter (Q2) ended September 30, 2026, compared to a loss of ₹99 crore in the same quarter last year. Its revenue from operations stood at ₹2,617 crore for the quarter…
3 Big Pharma Earnings Reports to Watch: Eli Lilly, Merck and Gilead
Eli Lilly's EPS estimate collapsed by a third in just 30 days, Merck faces a comparison it cannot repeat, and Gilead is burning through cash fast. Three pharma giants report Thursday, and the results could reshape the sector's outlook for……
IT stocks, Reliance drag markets lower at midday; Pharma outperforms as Fed decision looms
Equity benchmarks pared some of their early losses by mid-session on Wednesday but remained firmly in the red, with information technology stocks and Reliance Industries continuing to weigh on sentiment even as broader markets and select defensives…
Marshall purchased stock in obscure pharma company just before it secured key FDA approval
On November 8, 2018, then-Congressman Roger Marshall (R-KS) and his wife completed a purchase of 1,250 shares of Ionics Life Sciences, a privately held company, according to documents from the Irish Companies Registration Office obtained by Popular…
Piramal Pharma Q2 results: Company swings to ₹5 crore profit
Piramal Pharma on Thursday reported a consolidated net profit of Rs 5 crore in the July-September period of the current fiscal year. The pharma company had posted a loss of Rs 99.22 crore in the year-ago period, the company said in a regulatory…
NewAmsterdam Pharma (NAMS) Set to Release Quarterly Earnings on Wednesday
NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) is projected to release its Q3 2026 results before the market opens on Wednesday, November 4th. Analysts expect the company to announce earnings of ($0.4949) per share and revenue of $7.54 million…
Astellas Bets Up to $1.3 Billion on Cancer Drug Yet to Enter Human Trials
Astellas Pharma Inc. agreed to pay as much as $1.34 billion for rights to an experimental cancer treatment from Melbourne-based Audax Biosciences that has yet to be tested in humans. Audax will receive an upfront payment and potentially another…
Swiss cantons give green light for modernisation of EuroAirport
The project involves the investment of €157 million (CHF145 million) and is aimed at modernising the infrastructure and improving passenger handling. The airport authorities will finance the project, the two Basel cantons said on Tuesday.
Cardiff Oncology Names Alland Interim Chief Medical Officer as Sidhu Steps Down
Cardiff Oncology said that Chief Medical Officer Roger Sidhu has stepped down. The company disclosed Sidhu's exit on Tuesday and appointed Leila Alland as interim chief medical officer. Alland previously was chief medical officer at companies…
Melbourne cancer therapy start-up wins $2b deal with Japan's Astellas
A Melbourne start-up owned by a small group of medical researchers has landed one of Australia's biggest potential biotech licensing deals after Japanese pharmaceutical giant Astellas Pharma agreed to pay up to $2 billion for future rights to…
Xenia Hotels: A Buy Ahead Of Q3 Results, Betting On Continued Portfolio Quality (NYSE:XHR)
Albert Anthony is the pen name of a business author on Amazon and his newest book is 'How To Pick Stocks: 8 Steps For Long-Term Investing with Fundamental & Technical Analysis,' now available as a 2026 edition paperback and Kindle ebook in several…
AbbVie: Analyzing Performance, Pipeline, And Pricing Ahead Of Q3 (Strong Buy) (NYSE:ABBV)
AbbVie Inc. is trading at all-time highs, with robust 2026 guidance and a market cap exceeding $500bn. I expect ABBV Q3 earnings to outperform, driven by immunology assets Skyrizi and Rinvoq, which together will generate over $30bn in 2026. Despite…
Receive a Daily briefing on Pharma Industry News
Get Started